Head-to-head evidence
adalimumab vs CT-P17
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Rheumatoid Arthritis
Shared mechanism: TNF-alpha · full Rheumatoid Arthritis pipeline
adalimumab · Humira
Marketed by AbbVie and partners
NCT00195702 · Phase 3 · completed
This was a large, randomized, double-blind, placebo-controlled trial. More patients on adalimumab responded on the ACR20 joint-response measure than on placebo (about 61-63% vs about 30%, p<0.001 for both doses), and adalimumab also significantly slowed radiographic joint damage and improved physical function compared with placebo (p<0.001 for both).
Next expected readout: February 2027 · NCT06972446 (registry estimate)
CT-P17
Developed by Celltrion
NCT03789292 · Phase 3 · completed
The trial was a large randomized, quadruple-blind comparison of CT-P17 and Humira, with 324 participants per initial treatment group. Its primary clinical endpoint, ACR20 response at Week 24, had identical reported counts in both groups, but the registry does not state whether the prespecified statistical comparison met its criterion, so the result is unclear.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab's landscape · CT-P17's landscape